Note: for more in-depth information about each priority on the NBCC website.
Breast cancer is a not only an issue for all of us to be concerned and affected in some way, it is also a highly political issue. The federal government is the largest funder of biomedical research. Laws regulate and support access to care and health care systems. Third party payers are subject to state and federal regulations. In fact, every aspect of breast cancer is touched by public policy. It is key that those who influence that policy are educated and trained and have no agenda other than to save lives, and to end breast cancer.
PRIORITY #1 $150 Million for the Department of Defense (DOD) Breast Cancer Research Program (BCRP) for FY2018: As a result of NBCC’s grassroots advocacy, the DOD BCRP was created in 1992 to “eradicate breast cancer by funding innovative, high-impact research through a partnership of scientists and consumers.” The DOD BCRP is widely viewed as an innovative, unique, and efficient medical research model which has proven to be accountable to the public and has produced extraordinary results. NBCC seeks continued funding for this successful program.
A bill to add Metastatic Breast Cancer as a Qualifying Condition for Medicare Coverage. This legislation would waive all waiting periods for Medicare eligibility on the basis of disability for all individuals with metastatic breast cancer and provide Medicare health care coverage including drugs and biologicals and all intervention used for the treatment and alleviation of symptoms relating to metastatic breast cancer.
Preservation of the Medicaid Breast and Cervical Cancer Treatment Program: Congress enacted the Breast and Cervical Cancer Treatment Act in 2000 after years of NBCC grassroots lobbying and influence. NBCC remains committed to ensuring all women and men screened and diagnosed with breast cancer through federal screening programs have access to the treatment they need.
NBCC's Clinical Trials Partnerships Upcoming Clinical Trials for Women with Metastatic Breast Cancer
NBCC is currently partnering with BioMarin and Pfizer on three upcoming clinical trials for women with metastatic breast cancer. Intervention offers the potential of improving the length and quality of life for patients already diagnosed with metastatic breast cancer. Trial accrual has begun for all three studies.
NBCC advocates have been involved in many ways on these trials in the development of the protocols, as members of the Data Safety Monitoring Board, as reviewers of educational materials and consent forms and in conducting outreach activities to educate the public about the trials.
Eligibility: Women with HR+/HER2- locally advanced or metastatic breast cancer who progressed on or after prior endocrine therapy. Other eligibility criteria and trial details can be found at:
NBCC is recruiting advocates to help educate the public and potential participants about these trials. If you are interested in helping NBCC's outreach effort for any of these trials, please contact NBCC at email@example.com.
SLBCC is a member organization of the National Breast Cancer Coalition (NBCC), headquartered in Washington, D.C., which has grown to more than 600 member organizations across the country.